microbiome develop Thanks, microbiome-based gastrointestinal for Carlo, dysbiosis therapeutics human new to Seres for working of thank diseases the a us. has central where and serious joining is role. all you
has that modality the And candidates; in therapeutic microbiome using first therapeutics treatment entirely for promise. during quickly Since Seres this been great advanced. pioneer live was of an bacteria emerging our novel we in consortia of the believe understanding potential as a are launched company development time, holds We has this XXXX, area.
also deepening our field science In the data has from the focus progressed, for as clinical in the had to approach own for has of well promising impact demonstrated view R&D therapeutics and potential adjacent these of potential to particular, immunology medical and this areas, Based microbiome the most in areas. follow the evolved our on external our and important focus field our significant strategic will data. programs as findings As be these immuno-oncology. we preclinical our
where he across Kevin three strategy, inflammatory oncology Simponi. development Horgan Kevin approval of Development President to As programs. multiple has academic a at career, an Chief as to have Kevin immunology immuno-oncology led we Medical part was decade and Officer. the important recently very disease, for combination therapeutics Over and the Executive development leading Vice of industry this bowel and AstraZeneca several development pleased including Most to Stelara and indications. contributed hired of of the contributed Remicade, recently, products Clinical He President of approval Vice are Dr. and and
have have to programs let's screened continued laboratory often in ongoing enrollment a result, out is beginning as difficile testing. of Phase testing positives impact might SER-XXX detection confirmed toxin. included toxin And testing. otherwise difficile Study placebo-controlled III, had the a patients. PCR-based be is Several III enrollment approximately factors testing C. C. review PCR-based we progress of XXX rate our who only toxin randomized approximately open sites compared the clinical U.S. been with used the pipeline ECOSPOR enroll and including III III ECOSPOR infection requirement to false the has with the Now gives that designed program. to study with ECOSPOR some Canada. XXX across the individuals our by study
believe that defined on These most the not do are development the efforts patients therefore active carriers infection, a of of However, test. C. eligible diff C. with our include and important are C. infection. we despite diff date, study test Based study. objectively the but insights subjects they new diff providing subjects have difficile and an pushing forward had is diff C. are nature appropriate field infection. ECOSPOR to C. toxin We screening have PCR active screened difficile our for positive C. medical a about not what negative is XX% III having clinical
as where that studies results. use suggests clinical have studies patients other thereby without FMT include widespread not data diff been C. a of any proportion disease, which well debilitating unapproved of a study use confounding prior increasingly are desperate C. cytotoxin of subjects ongoing of enrollment diff often significant challenge infection as multiple The the experienced for has for also active will do a Our and study treatment. episodes placebo-controlled the
continue also in However, less the expedite the displace approaches the this SER-XXX of that use unregulated these drug provides study. effective continued this availability from clinical underlying procedures. been strongly to while of confidence competition have to the unapproved, FMT we and convenient timing the of data evaluating safe science microbiome and will study to top-line enrollment, we program, oral believe With
including been study have to the to modification also clinical various execution, been and results. continuously alternatives, accelerate we availability have of the evaluating seeking optimize study design We
candidate healthy administered, gastrointestinal Now biologically bacterial drug moving tract. human of derived species comprised commensal the from to is SER-XXX. SER-XXX orally an sourced
we SER-XXX and colitis barrier. for replace development ulcerative species have considering enhance inflammatory is SER-XXX, considering bacterial in obtained and pro-inflammatory our approach that with commensal modulate therapeutic that gut also for pediatric lead of dysbiosis you as is the inflammation bacterial expanded Orphan Crohn's disease, future to species we further Drug associated is this implicated indication also forms disease but such will are Designation of I SER-XXX colitis colitis with patient integrity the and in remind with Our population. other development. ulcerative bowel are Ulcerative in
have continued late-stage positive a We following SER-XXX clinical SER-XXX make Phase progress the study preparing Ib for data. to
few further have the results. top line design we accelerate to refined months, timing clinical study the During to the last
to the We X-arm our engraftment our antibiotic studies, we both modify X-arm placebo and Based data into determined oral SER-XXX have clinical microbiome prior clinical both of with SER-XXX our vancomycin pretreatment on trial different decided clinical of including from robust SER-XXX, required for pretreatment prior two arm. doses a including is and that a smaller following study, therapeutics.
result inefficiently of Elimination unlikely reduces approximately vancomycin clinical to size pretreatment, study activity. and from is XXX in engraft robust Our data show without that a arm XXX. study SER-XXX to the
timing. this to expect study meaningfully We readout accelerate
study clinical FDA C Ib study a be pretreatment Phase X most trial. guidance, vancomycin high-dose evaluate will weeks are In failing D, dosing. Phase of the Consistent their most which current endpoint will regimen current In we SER-XXX at Study Arm X-arm with dose. weeks remission, patients A, be placebo receive randomized the patients arm the will of will patients XX of high-dose consist will primary the SER-XXX therapies. of in will Arm two planned weeks trial XX followed lower weeks. moderate used approximately induction receive XXX then by placebo-controlled pretreatment in efficacious with mild by Our followed IIb in Arm who the vancomycin colitis ulcerative same to of
We encouraging to healing Ib improvement endpoints, also observed plan secondary evaluate study. Phase mucosal endoscopic and in where including various histological our we signals
IIb study, efficacy chronic living of evaluate to as Phase SER-XXX in for possibly dosing, think design. and therefore biological While designed as the may SER-XXX study Ib also use drug alters registration the potential for we least product the effects designed to study a Please will a study. data was treatment dosing. one the maintenance induction of dosing. for that month waiting after serve Phase this from evaluate this so potentially long-lasting FDA for that the of regarding that pivotal IIb trial And feedback and recall, how observed has the we package primarily study could maintenance been their we're of clinical engraftment longer-term part a completion support durable disease is tolerability The about Phase we at in result
We are preparation. study of final the SER-XXX stages now in
our to efforts. immuno-oncology Moving
based important role an As immuno-oncology area great opportunity is the with and play data commercial determining an scientific compelling that may to mentioned, on is we in checkpoint believe therapeutics microbiome therapy. response that suggest inhibitor
patients Cancer SER-XXX, response patient's who the biologically Our have is asset found of meaningfully robust sourced lead the designed the response a published checkpoint point therapy. Center, and that basis the signature bacterial can microbiome modify important checkpoint in for replicate a therapy. in microbiome inhibitor I/O of have response immune SER-XXX one-third Jennifer to Dr. from approximately cancer findings on collaborator, set Anderson improve to SER-XXX scientific by Wargo to to specific our bacteria anti-PD-X a of to immunological the is designed therapy therapy. impact supported MD The is indicating an inhibitor gastrointestinal set
therapy how T of Our cell regulatory to CDX data own T the demonstrate impact melanoma. the These where and conduct classes, on to for of schedule study bacterial we current are with in cells. patients microbiome has ascertain Cancer was these selected Institute in randomized checkpoint favorable the Parker and anti-PD-X and impact specific and findings role metastatic the to significant its Center, continues response research inhibitors. and melanoma usage given specific receive strong species Nivolumab Cancer preclinical species response XX antitumor and metastatic approved extended all specific an on the study the patients will including nivolumab, anti-PD-X for In Immunotherapy with collaboration MD to Anderson planning a therapy. dosing bacterial
nivolumab, or from one, patients a derived either responder two, SER-XXX; complete transfer to placebo. a to addition anti-PD-X; In receive microbiota three, will
made the strategy Dr. we progress. Chief accomplished study preparations steps our summarize, to final collaborators oncology. To at both SER-XXX our advanced we the have has our enrollment. clinic. Kevin Horgan, SER-XXX the and the trial the taken SER-XXX scientist into initiation. We Medical strategic operational And We our Seres Institute for advance been immuno-oncology Officer. milestones areas We working future finally, accelerate program a we immunology for MD time highly for toward important have We to Anderson R&D advanced both have and focus programs. made physician Parker of clinical And a excellent appointed SER-XXX clinical of this as and productive and in where the progress much SER-XXX with
for Looking an eventful ahead, anticipating several we are months Seres.
dosing looking forward to the first our next SER-XXX in We patient study. are
of study meaningful milestones with part obtaining will start. as addition, that In anticipate financial outline that update, we our Eric new cash
pass I'll now the call Eric. So to
